Company Overview
Snapshot
Founded in January 2018 by Or Bruch-El, MedHub-AI operates with 11–50 employees. The company has raised $11.57 million across 9 funding rounds from 3 investors. In October 2025, MedHub-AI's AutocathFFR™ System received national reimbursement approval in Japan from the Ministry of Health, Labour and Welfare, following earlier regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA).
Business overview
MedHub-AI develops deep-learning video analysis algorithms to provide accurate diagnostic insights and practical guidance for physicians, primarily serving the cardiology and gastroenterology markets. Its technology processes large volumes of clinical visual and textual data to improve physician performance and shorten procedure times. The company's solutions, including the CE and AMAR approved AutocathFFR system, are designed to be integrated into medical video systems, offering a multilayered automated system from diagnosis through procedural guidance and documentation. MedHub-AI operates within the Digital Healthcare and Medical Decision Support sectors, targeting healthcare providers and insurance companies.
Strategic signal
MedHub-AI achieved a significant market validation in October 2025 with national reimbursement approval in Japan for its AutocathFFR™ System. This approval from the Japanese Ministry of Health, Labour and Welfare, following prior regulatory clearance, is a strong indicator of the system's clinical utility and economic value. It signals to investors and innovation teams a clear pathway for commercial expansion and increased market penetration in a key international healthcare market, reinforcing the company's growth trajectory and the potential for its AI-based coronary artery disease assessment technology.
Log in to access full profile ›Company Intelligence Q&A
- What significant market approval did MedHub-AI recently receive?
- In October 2025, MedHub-AI's AutocathFFR™ System received national reimbursement approval from the Japanese Ministry of Health, Labour and Welfare, following earlier regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA).
- What strategic partnership did MedHub-AI establish for the Japanese market?
- In June 2025, MedHub-AI announced a distribution agreement with Terumo Corporation to introduce its AI-powered software, AutocathFFR®, to the Japanese market.
- Who was appointed as President of MedHub-AI?
- In July 2023, MedHub-AI appointed Dr. Justin Davies, a medical device industrial expert and cardiac care innovator, as its President.
- What was a key development for MedHub-AI in February 2022?
- In February 2022, MedHub-AI completed a pivotal multi-center validation study for its AutocathFFR™ system and secured funding from investors including Ron Zuckerman and Prof. Rafael Beyar.
- When did MedHub-AI receive CE Mark approval for its AutocathFFR software?
- In September 2020, MedHub-AI received CE Mark certification for its AutoCathFFR system, allowing it to market the system in European countries.